{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:43:12Z","timestamp":1790746992389,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.amjmed.2017.02.010","type":"journal-article","created":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T02:00:36Z","timestamp":1489024836000},"page":"635-639","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Sacubitril\/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure"],"prefix":"10.1016","volume":"130","author":[{"given":"Jo E.","family":"Rodgers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.amjmed.2017.02.010_bib1","first-page":"e29","article-title":"Heart disease and stroke statistics\u20142015 update: a report from the American Heart Association","volume":"131","author":"Mozaffarian","year":"2015","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.amjmed.2017.02.010_bib2","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the united states a policy statement from the american heart association","volume":"6","author":"Heidenreich","year":"2013","journal-title":"Circ Heart Fail"},{"issue":"18","key":"10.1016\/j.amjmed.2017.02.010_bib3","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.110.979500","article-title":"Natriuretic peptide testing in heart failure","volume":"123","author":"Kim","year":"2011","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.amjmed.2017.02.010_bib4","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jchf.2014.09.001","article-title":"Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure","volume":"2","author":"Vardeny","year":"2014","journal-title":"JACC Heart Fail"},{"issue":"4","key":"10.1016\/j.amjmed.2017.02.010_bib5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0091270009343932","article-title":"Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)","volume":"50","author":"Gu","year":"2010","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.amjmed.2017.02.010_bib6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1517\/14656566.2015.1000300","article-title":"LCZ696: a new paradigm for the treatment of heart failure?","volume":"16","author":"Minguet","year":"2015","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"10.1016\/j.amjmed.2017.02.010_bib8","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.amjmed.2017.02.010_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/CIRCHEARTFAILURE.115.002744","volume":"9","author":"Solomon","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"19","key":"10.1016\/j.amjmed.2017.02.010_bib10","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.jacc.2015.08.878","article-title":"Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF","volume":"66","author":"Simpson","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.amjmed.2017.02.010_bib11","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003212","article-title":"Effects of sacubitril\/valsartan in the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy","volume":"9","author":"Okumura","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"10","key":"10.1016\/j.amjmed.2017.02.010_bib12","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jchf.2016.05.002","article-title":"Efficacy of sacubitril\/valsartan relative to a prior decompensation: the PARADIGM-HF Trial","volume":"4","author":"Solomon","year":"2016","journal-title":"JACC Heart Fail"},{"issue":"3","key":"10.1016\/j.amjmed.2017.02.010_bib13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jacc.2016.04.047","article-title":"Influence of sacubitril\/valsartan (LCZ696) on 30-day readmission after heart failure hospitalization","volume":"68","author":"Desai","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.amjmed.2017.02.010_bib14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.amjmed.2017.02.010_bib20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamacardio.2016.4733","article-title":"Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonist by use of sacubitril\/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial","volume":"2","author":"Desai","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjmed.2017.02.010_bib21","series-title":"Entresto [Package Insert]","year":"2015"},{"issue":"30","key":"10.1016\/j.amjmed.2017.02.010_bib22","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1093\/eurheartj\/ehv186","article-title":"Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients","volume":"36","author":"Desai","year":"2015","journal-title":"Eur Heart J"},{"issue":"14","key":"10.1016\/j.amjmed.2017.02.010_bib23","first-page":"e282","volume":"134","author":"Yancy","year":"2016","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.amjmed.2017.02.010_bib24","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/CIRCULATIONAHA.115.018622","article-title":"Combined angiotensin receptor antagonism and neprilysin inhibition","volume":"133","author":"Hubers","year":"2016","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.amjmed.2017.02.010_bib25","first-page":"e29","article-title":"Cost-effectiveness analysis of sacubitril\/valsartan vs enalapril in patients with heart failure and reduced ejection fraction","volume":"131","author":"Gaziano","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"5","key":"10.1016\/j.amjmed.2017.02.010_bib26","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jchf.2016.02.007","article-title":"Cost-effectiveness of sacubitril\/valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction","volume":"4","author":"King","year":"2016","journal-title":"JACC Heart Fail"},{"issue":"6","key":"10.1016\/j.amjmed.2017.02.010_bib28","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1001\/jamacardio.2016.1724","article-title":"Potential mortality reduction with optimal implementation of angiotensin receptor neprilysin inhibitor therapy in heart failure","volume":"1","author":"Fonarow","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"7","key":"10.1016\/j.amjmed.2017.02.010_bib29","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/eurheartj\/ehu455","article-title":"A\u00a0putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure","volume":"36","author":"McMurray","year":"2015","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.amjmed.2017.02.010_bib30","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMc1509753","article-title":"Estimating the long-term treatment benefits of sacubitril\/valsartan","volume":"373","author":"Claggett","year":"2015","journal-title":"N\u00a0Engl J Med"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934317302164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934317302164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:10:25Z","timestamp":1757581825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934317302164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0002934317302164"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2017.02.010","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sacubitril\/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2017.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}